Our Programs
Reactive oxygen species (ROS), the fundamental cause of more than 90% of chronic disease, is unstable reactive oxygen species, which accumulation of excessive amount cause series of damages to human cells and ultimately organs. Humans are born with Superoxide Dismutase (SOD), an antioxidant enzyme that can defend against ROS, but amount and activity continually decrease as we age.
Genofocus is developing high-purity SOD, antioxidant enzyme, produced using microbial engineering & secreting expression technologies to develop SOD into therapeutic molecule. 4 Korea domestic patents and 1 US patent has been successfully registered. SOD producing strain is the first strain patent obtained in Korea, which has been developed as new drug to exert continuous antioxidant effect, removing ROS, to restore human homeostasis.
SOD-based pharmaceutical candidate substance.
GF-101 : Wild Type
- Nutraceutical ingredients
- Efficacy validation through clinical studies & new application exploration
GF-103 : Mutant
- High-purity therapeutic protein
- Global clinical trials for IBD and AMD treatments
GF-203 : Spore
- Efficacy improved microbial therapeutics
- Production of SOD and different MOA possessing effector molecules in the intestines.
- Maximize therapeutic effects
GF-303 : EV
- Extracellular Vesicle (EV)
- SOD loaded extracellular vesicle (EV)
- Respiratory therapeutics development in progress
Novel microbiome-enzyme drug candidate.
- Safety
- Pharmaceutical/food microorganism (GRAS)
derived drug candidate ensuring safety
- CoGs
- Price competitiveness achieved by
securing enzyme/microbial
new drug production plant
- Efficacy
- Clinical studies to pre-verify
beneficial effects on human,
enabling biomarker elucidation
- Delivery
- Spore delivery
→ Gastric acid, bile acid, and protease resistant - Maximizing probiotic effect
- Combination
- Combination of existing drugs
and therapeutic enzyme considering
each MOA to achieve synergistic effect